Royalty Pharma (NASDAQ:RPRX) Hits New 12-Month Low at $25.84

Royalty Pharma plc (NASDAQ:RPRX) shares hit a new 52-week low on Tuesday . The stock traded as low as $25.84 and last traded at $25.92, with a volume of 1225141 shares traded. The stock had previously closed at $26.19.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on RPRX. UBS Group cut shares of Royalty Pharma from a “buy” rating to a “neutral” rating and set a $28.00 price target for the company. in a research report on Monday, June 3rd. Bank of America cut their price target on shares of Royalty Pharma from $40.00 to $38.00 and set a “buy” rating on the stock in a research note on Friday, April 12th. Finally, StockNews.com lowered shares of Royalty Pharma from a “buy” rating to a “hold” rating in a research note on Friday, May 10th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $43.00.

Royalty Pharma Price Performance

The stock has a market cap of $15.46 billion, a price-to-earnings ratio of 19.31, a price-to-earnings-growth ratio of 3.44 and a beta of 0.46. The stock’s 50 day moving average price is $27.33 and its two-hundred day moving average price is $28.48. The company has a quick ratio of 12.52, a current ratio of 12.52 and a debt-to-equity ratio of 0.62.

Royalty Pharma (NASDAQ:RPRX) last released its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported $0.98 EPS for the quarter, beating the consensus estimate of $0.96 by $0.02. The company had revenue of $568.00 million for the quarter, compared to analyst estimates of $671.45 million. Royalty Pharma had a net margin of 35.70% and a return on equity of 22.94%. During the same quarter last year, the business earned $1.60 earnings per share. Equities research analysts forecast that Royalty Pharma plc will post 4.03 EPS for the current fiscal year.

Royalty Pharma Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, June 14th. Shareholders of record on Friday, May 17th were issued a dividend of $0.21 per share. This represents a $0.84 annualized dividend and a yield of 3.25%. The ex-dividend date was Thursday, May 16th. Royalty Pharma’s payout ratio is 62.69%.

Hedge Funds Weigh In On Royalty Pharma

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Fidelis Capital Partners LLC purchased a new position in shares of Royalty Pharma in the first quarter worth about $46,000. Allworth Financial LP lifted its stake in shares of Royalty Pharma by 76.7% in the fourth quarter. Allworth Financial LP now owns 1,684 shares of the biopharmaceutical company’s stock worth $47,000 after buying an additional 731 shares in the last quarter. GAMMA Investing LLC lifted its stake in shares of Royalty Pharma by 172.5% in the first quarter. GAMMA Investing LLC now owns 1,638 shares of the biopharmaceutical company’s stock worth $50,000 after buying an additional 1,037 shares in the last quarter. EverSource Wealth Advisors LLC lifted its stake in shares of Royalty Pharma by 79.8% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,807 shares of the biopharmaceutical company’s stock worth $51,000 after buying an additional 802 shares in the last quarter. Finally, Lindbrook Capital LLC increased its position in Royalty Pharma by 485.2% during the fourth quarter. Lindbrook Capital LLC now owns 2,411 shares of the biopharmaceutical company’s stock worth $68,000 after purchasing an additional 1,999 shares during the last quarter. 54.35% of the stock is owned by hedge funds and other institutional investors.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.